Stay up-to-date with the latest developments in securities law through access to both news and all statutes and regulations. Find relevant corporate filings through a searchable EDGAR database. And...
Tennessee-based Provectus Biopharmaceuticals Inc. Dec. 12 settled SEC allegations it failed properly to report as compensation millions of dollars in perks provided to its then-top executives.
Provectus didn’t have adequate controls over the reporting and disclosure of travel and entertainment expenses submitted by its executives, the Securities and Exchange Commission said.
“The SEC’s settlement with Provectus — which does not include any penalty — takes into account the proactive remediation and cooperation by the company’s new leadership,” co-Enforcement Director Steven Peikin said. “Provectus fired wrongdoers, took other steps to remedy its controls, and provided SEC staff with critical information regarding its former executives’ expense reimbursement abuses.”
At the same time, Peter Culpepper, the concern’s former chief financial officer, settled allegation he obtained almost $200,000 in unauthorized, undisclosed benefits. Culpepper will pay $152,376 in disgorgement and interest, plus a $90,535 civil penalty, and will be suspended from appearing before the SEC as an accountant for at least three years.
Former Provectus chief executive officer H. Craig Dees, who is representing himself, was sued in the U.S. District Court for the Eastern District of Tennessee for allegedly submitting “little, no, or fabricated” expense reports and other documents to obtain $3.2 million in cash advances and reimbursements for business travel he never took.
“Instead, he concealed the perks and used cash advances to pay for personal expenses such as cosmetic surgery for female friends, restaurant tips, and personal travel,” the SEC said. It is asking the court to order disgorgement plus prejudgment interest, civil money penalties, an officer/director bar, and an injunction against future violations.
The cases are In re Provectus Biopharmaceuticals Inc. , S.E.C., Admin. Proc. File No. 3-18306, 12/12/17 ; In re Culpepper , S.E.C., Admin. Proc. File No. 3-18308, 12/12/17 ; SEC v. Dees , E.D. Tenn., 3:17-cv-00532, 12/12/17
To contact the reporter on this story: Phyllis Diamond in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Seth Stern at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)